Arcadia Biosciences Swings to $4.4M Net Loss in Q1, Operating Expenses Soar 180%
RKDA sits 20% above its 52-week low of $0.89.
Summary
Arcadia Biosciences reported a significant net loss of $4.4 million, or $2.11 per share, for the first quarter of 2026, a sharp decline from a net income of $2.6 million in the prior year period. Total revenues decreased 8% to $1.1 million, while total operating expenses surged 180% to $1.88 million, largely due to the absence of prior year gains. This substantial deterioration in financial performance follows the company's recent 10-K filing, which included a going concern warning and a Nasdaq delisting threat, intensifying concerns about its financial viability. While the company noted positive operational highlights such as 18% year-over-year Zola volume growth and the lowest SG&A in its history, these were overshadowed by the overall financial losses, including a $2.9 million loss from a warrant inducement offer. Traders will be closely monitoring the company's ongoing evaluation of strategic alternatives and its ability to address its severe financial distress.
At the time of this announcement, RKDA was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.89 to $6.71. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.